Show simple item record

dc.creatorMilić, Vera
dc.creatorJekić, Biljana
dc.creatorLuković, Ljiljana
dc.creatorBunjevački, Vera
dc.creatorMilašin, Jelena
dc.creatorNovaković, I.
dc.creatorDamnjanović, Tatjana
dc.creatorPopović, Branka
dc.creatorMaksimović, Nela
dc.creatorDamjanov, Nemanja
dc.creatorRadunović, Goran
dc.creatorPejnović, Nada
dc.creatorKrajinović, Maja
dc.date.accessioned2020-07-02T12:40:37Z
dc.date.available2020-07-02T12:40:37Z
dc.date.issued2012
dc.identifier.issn0392-856X
dc.identifier.urihttp://smile.stomf.bg.ac.rs/handle/123456789/1741
dc.description.abstractObjectives Identifying genetic predictors of methotrexate (MTX) treatment response in patients with rheumatoid arthritis (RA) may have great importance for optimising drug doses required for clinical benefit without toxicity. In a group of 125 RA patients treated with MTX we investigated whether selected polymorphisms in genes relevant for MTX action (aminoimidazole-4-carboxiamide ribonucleotide transformylase, ATIC, and dihydrofolate reductase, DHFR) modulate disease activity and/or have impact on therapy side effects. Methods The efficacy of treatment was estimated both by the disease activity score in 28 joints (DAS28), based on EULAR criteria, and relative DAS28 (rDAS28) score. Adverse drug events (ADEs) were also recorded. RA patients were genotyped using the PCR-RFLP method, followed by an association study between ATIC -129T>G, DHFR -216T>C and DHFR -317A>G polymorphisms and the efficacy and toxicity of MTX. Results According to the EULAR response criteria, 96 RA patients (76.8%) were classified as responders (good/moderate response) and 29 (23.2%) as non-responders (poor response). rDAS28 values ranged from -0.01 to 0.80 (mean value 0.31 +/- 0.19). Among 125 patients enrolled in this study 39 experienced at least one side effect. The DHFR -317AA genotype was associated with the less favourable response (reduction in rDAS28 score, p=0.05). None of the analysed polymorphisms was associated with MTX toxicity. Conclusion RA patients with DHFR-317AA genotype had less favourable response to MTX Further studies in larger patient populations are necessary to confirm the relationship between the analysed polymorphisms and MTX treatment response.en
dc.publisherClinical & Exper Rheumatology, Pisa
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175091/RS//
dc.rightsrestrictedAccess
dc.sourceClinical & Experimental Rheumatology
dc.subjectmethotrexateen
dc.subjectDHFRen
dc.subjectATICen
dc.subjectpolymorphismsen
dc.subjectrheumatoiden
dc.titleAssociation of dihydrofolate reductase (DHFR)-317AA genotype with poor response to methotrexate in patients with rheumatoid arthritisen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractНоваковић, И.; Пејновић, Нада; Поповић, Бранка; Јекић, Биљана; Милић, Вера; Радуновић, Горан; Дамјанов, Немања; Крајиновић, Маја; Максимовић, Нела; Дамњановић, Татјана; Буњевачки, Вера; Луковић, Љиљана; Милашин, Јелена;
dc.citation.volume30
dc.citation.issue2
dc.citation.spage178
dc.citation.epage183
dc.citation.other30(2): 178-183
dc.citation.rankM22
dc.identifier.wos000303905800006
dc.identifier.pmid22324981
dc.identifier.rcubconv_2995
dc.type.versionpublishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record